The monotherapy anti-PD-L1 (15.02%) showed significantly higher cytotoxicity against cancer cells compared to the control group (2.14%) (p < 0.05) and the combination therapy anti-PD-L1 + anti-VISTA (6.38%) (p < 0.05). The gene discussed is CD274; the disease is cancer.